S. Rahimian

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Immunology, Oncology +16

Advances in Exosome-Based Therapies for the Repair of Peripheral Nerve Injuries

S. Rahimian, Hossein Najafi, Christine A. Webber et al. · Neurochemical Research · 2024 · 22 citations

Medicine, Neuroscience, Surgery +14

1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma

Cara Haymaker, Robert H.I. Andtbacka, Douglas B. Johnson et al. · Annals of Oncology · 2020 · 20 citations

Pharmacy, Oncology, Pharmacotherapy +17

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

Adi Diab, Cara Haymaker, Chantale Bernatchez et al. · Annals of Oncology · 2018 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17